Arca
Skip to content
Tools
Tools

Hyperoxaluria

Drug research and approvals for hyperoxaluria: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 19, 2026, 16 studies of hyperoxaluria are recruiting on ClinicalTrials.gov, Health Canada has authorized 6 drug trials for it since 2013, FDA has 4 approved and 8 open orphan designations naming it, and the EU has 1 authorised medicine for it.

  • Recruiting worldwide: 16
  • Trials authorized in Canada: 6
  • FDA orphan approvals: 4
  • EU medicines: 1

Recruiting now

Newest posted first, of 16 recruiting on ClinicalTrials.gov ↗

Trials authorized in Canada

Newest first; search them all in Canada trials
Jul 14, 2022Phase 1-2a safety, tolerability, and pharmacodynamics controlled study of NOV-001 in healthy volunteers and patients with enteric hyperoxaluriaNOV-001 (NB1000S / NB2000P)Novome Biotechnologies, Inc.Ongoing
Jul 6, 2021A phase 2 open-label multicenter study to evaluate the safety, pharmacokinetics, and efficacy of nedosiran in pediatric patients from birth to 5 years of age…Nedosiran (dcr-phxc)Dicerna Pharmaceuticals IncPending
Jul 10, 2019Evaluate the safety and efficacy of reloxaliase (oxalate decarboxylase) in patients with enteric hyperoxaluria: a phase III randomized, double-blind,…Reloxaliase (ALLN-177)Allena Pharmaceuticals IncOngoing
Mar 8, 2019An open-label roll-over study to evaluate the long-term safety and efficacy of dcr-phxc solution for injection (subcutaneous use) in patients with primary…Nedosiran (dcr-phxc)Dicerna Pharmaceuticals IncOngoing
Jan 21, 2019A phase 2 placebo-controlled, double-blind, multicenter study to evaluate the efficacy, safety, and tolerability of dcr-phxc solution for injection…Dcr-phxcDicerna Pharmaceuticals IncClosed
Aug 13, 2018A phase III double-blind, randomised study to evaluate the long-term efficacy and safety of oxabact in patients with primary hyperoxaluriaOxabact (OC5)Oxthera Intellectual Property ABPending

FDA orphan designations

Approved first, then open designations, newest first
Mar 27, 2025RivflozaTo lower urinary oxalate levels in children 2 years of age and older and adults with primary hyperoxaluria type 1 (PH1) and relatively…Dicerna Pharmaceuticals, Inc. (a wholly owned subsidiary of Novo Nordisk)Approved
Sep 29, 2023RivflozaTo lower urinary oxalate levels in children 9 years of age and older and adults with primary hyperoxaluria type 1 (PH1) and relatively…Dicerna Pharmaceuticals, Inc. (a wholly owned subsidiary of Novo Nordisk)Approved
Oct 6, 2022OxlumoTreatment of primary hyperoxaluria type 1 (PH1) to lower urinary and plasma oxalate levels in pediatric and adult patientsAlnylam PharmaceuticalsApproved
Nov 23, 2020OxlumoTreatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patientsAlnylam PharmaceuticalsApproved
Feb 2, 2025A lipid nanoparticle encapsulating a messenger RNA for the…Treatment of primary hyperoxaluriaArbor Biotechnologies, Inc.Designated
Sep 20, 2024Lipid nanoparticles containing CRISPR/Cas12HF mRNA and a…Treatment of primary hyperoxaluriaYoltech Therapeutics Co., LtdDesignated
Aug 21, 2024A small molecule dual inhibitor of the enzymes LDHA and…Treatment of primary hyperoxaluriaMeta Pharmaceuticals (HK) LtdDesignated
Feb 22, 2021StiripentolTreatment of Primary HyperoxaluriaBiocodexDesignated
Jun 12, 2017Bacillus subtilis oxalate decarboxylaseTreatment of primary hyperoxaluriaAllena Pharmaceuticals, Inc.Designated
Feb 29, 2016Bacillus subtilis oxalate decarboxylaseTreatment of pediatric hyperoxaluriaAllena Pharmaceuticals, Inc.Designated
Apr 22, 2015Synthetic double-stranded (hybridized duplex) ribonucleic…Treatment of primary hyperoxaluria type 1Dicerna Pharmaceuticals, Inc.Designated
Mar 29, 2006Oxalobacter formigenesTreatment of primary hyperoxaluriaOxThera Inc.Designated

Medicines authorised in the EU

Newest first
AuthorisedMedicineHolderEPAR
Nov 19, 2020OxlumoLumasiran · orphanAlnylam Netherlands B.V.EMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.